NEOPHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25,450 KRW | -1.17% |
|
+9.46% | -1.55% |
| 2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
| Sales 2024 * | 120B 87.36M 7.29B | Sales 2025 * | 145B 106M 8.8B | Capitalization | 199B 145M 12.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 23B 16.74M 1.4B | Net income 2025 * | 30B 21.84M 1.82B | EV / Sales 2024 * | 0.59 x |
| Net cash position 2024 * | 128B 93.48M 7.8B | Net cash position 2025 * | 152B 111M 9.26B | EV / Sales 2025 * | 0.32 x |
| P/E ratio 2024 * |
9.1
x | P/E ratio 2025 * |
6.94
x | Employees | 142 |
| Yield 2024 * |
2.95% | Yield 2025 * |
2.95% | Free-Float | 56.96% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.17% | ||
| 1 week | +9.46% | ||
| Current month | +3.67% | ||
| 1 month | +1.80% | ||
| 3 months | -6.78% | ||
| 6 months | +4.73% | ||
| Current year | -1.55% |
1 week
23 550.00
26 600.00
1 month
22 350.0026 600.00
Current year
22 350.0029 450.00
1 year
17 470.0029 450.00
3 years
16 000.0039 000.00
5 years
16 000.0056 800.00
10 years
6 000.0063 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Woo-Jae Lim
BRD | Director/Board Member | 45 | 25/21/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Dong-Jin Choi
BRD | Director/Board Member | 64 | 21/19/21 |
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 25,450 | -1.17% | 31 080 |
| 26/24/26 | 25,750 | -0.19% | 27,810 |
| 25/24/25 | 25,800 | 0.00% | 95,597 |
| 24/24/24 | 25,800 | +6.61% | 117,058 |
| 23/24/23 | 24,200 | +2.76% | 48,554 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
NeoPharm Co., Ltd. is a Korea-based company engaged in the manufacture of cosmetics. The Company produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. It also engages in the original equipment manufacturing (OEM) of skin drugs.
Sector
Personal Products
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.55% | 146M | |
| +10.09% | 18.86B | |
| 0.00% | 17.37B | |
| -1.32% | 10.65B | |
| -7.61% | 10.26B | |
| +7.52% | 6.72B | |
| +10.34% | 5.94B | |
| +0.30% | 4.55B | |
| -18.19% | 3.83B | |
| -3.97% | 3.48B |
- Stock Market
- Equities
- A092730 Stock
